Mga Batayang Estadistika
| LEI | 529900NJUBI06118FM73 |
| CIK | 1625101 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pulse Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 2, 2025 |
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study Exhibit 99.1 Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study HAYWARD, Calif. [Business Wire]– September 2, 2025, Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-appro |
|
| August 26, 2025 |
Exhibit 99.1 Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid First-in-Human Clinical Feasibility Study Demonstrates Effectiveness of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation HAYWARD, Calif.-(BUSINESS WIRE) August 26, 2025- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive |
|
| August 12, 2025 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results HAYWARD, California. [Business Wire] – August 12, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended Ju |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 14, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc. |
|
| May 30, 2025 |
Exhibit 1.01 Conflict Minerals Report of Pulse Biosciences, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pulse Biosciences, Inc. (“Pulse Biosciences” or the “Company”) for the reporting period January 1, 2024 to December 31, 2024 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934, |
|
| May 8, 2025 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results HAYWARD, California. [Business Wire] – May 8, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31 |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Bioscie |
|
| April 30, 2025 |
Exhibit 10.27 December 5, 2024 VIA HAND DELIVERY Burke Barrett Dear Burke: The purpose of this letter is to inform you that Pulse Biosciences, Inc. (the “Company”) is accepting your resignation and consequently terminating your employment effective Friday, December 6, 2024 (your “Separation Date”). On your Separation Date, you will receive your final paycheck, which will include payment for all of |
|
| April 30, 2025 |
INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective May 11, 2022 Exhibit 19.1 INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective May 11, 2022 INTRODUCTION Federal and state securities laws prohibit any person who is aware of material nonpublic information about a company from trading in securities of that company. These laws also prohibit a person from disclosing material nonpublic information to other persons who may trade on th |
|
| March 31, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348 |
|
| March 31, 2025 |
Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of Incorporation Ownership Position NanoBlate Corp., a Delaware Corporation Delaware 100% BioElectroMed Corp., a California Corporation California 100% Pulse Biosciences BV Netherlands 100% 2783162 Ontario Inc. Ontario 100% |
|
| March 28, 2025 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results MIAMI, Florida. [Business Wire] – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31 |
|
| March 28, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Pulse Biosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 601 Brickell Key Drive, Suite 1080 Mi |
|
| February 27, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc. |
|
| February 27, 2025 |
PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY INCENTIVE PLAN Exhibit 4.4 PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Pulse Biosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 601 Brickell Key Drive, Suite 1080 Mi |
|
| February 27, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc. |
|
| February 4, 2025 |
Exhibit 10.1 PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Jon Skinner (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of January 31, 2025. 1. Duties and Scope of Employment. (a) Position and Duties. As of February 3, 2025 (the “Start Date”), Executive will serve as the Company’s Chief Financial Office |
|
| February 4, 2025 |
Exhibit 99.1 Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform MIAMI, Florida, February 4, 2025 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (n |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 23, 2025 |
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Exhibit 99.1 Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium Successfully treated atrial fibrillation (AF) in initial 30 patients with the Nanosecond PFA 360° Cardiac Catheter MIAMI, Florida. [Business Wire]– January 21, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveragi |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 21, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 14, 2025 |
Investor Deck, dated January 2025 Exhibit 99.1 |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 13, 2025 |
Exhibit 99.1 Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer Current Co-Chairman of the Board will now also serve as Chief Executive Officer MIAMI, Florida, January 10, 2025 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, tod |
|
| January 13, 2025 |
Exhibit 10.1 PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Paul LaViolette (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of January 9, 2025. 1. Duties and Scope of Employment. (a) Position and Duties. As of January 9, 2025 (the “Start Date”), Executive will serve as the Company’s President and Chief |
|
| December 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 26, 2024 |
PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS Exhibit 99.1 PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS HAYWARD, Calif. — (BUSINESS WIRE) — December 23, 2024 — Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, t |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 2, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 26, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 31, 2024 |
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association Exhibit 99.1 Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association European feasibility study demonstrates using nano-PFA in benign thyroid nodules reduces nodule volume by greater than 50% and provides symptomatic relief within the first month of treatment MIAMI, Florida. [Business Wire] – October 31, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a compa |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 Pulse Biosciences, Inc. |
|
| October 30, 2024 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results MIAMI, Florida. [Business Wire] – October 30, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 30, 2024 |
Exhibit 99.2 Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. MIAMI, Florida. [Business Wire] – October 30, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Fiel |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-37744 CUSIP Number: 74587B101 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2024 |
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results Exhibit 99.1 Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results HAYWARD, Calif. [Business Wire] – August 12, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financi |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2024 |
Exhibit 99.2 Pulse Biosciences, Inc. Appoints Paul LaViolette to its Board of Directors Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise MIAMI, Florida, August 12, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietar |
|
| August 12, 2024 |
Investor Deck, dated August 2024 EX-99.1 2 ex712662.htm INVESTOR DECK, DATED AUGUST 2024 Exhibit 99.1 |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024 Pulse Biosciences, Inc. |
|
| August 8, 2024 |
Exhibit 99.1 Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System Company’s proprietary system used in study for patients with atrial fibrillation Cardiac Surgery System enrolled in the FDA’s Total Product Life Cycle (TPLC) Advisory Program (TAP)* MIAMI, Florida, August 8, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) ( |
|
| July 15, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 15, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc. |
|
| July 15, 2024 |
As filed with the Securities and Exchange Commission on July 15, 2024 S-3MEF As filed with the Securities and Exchange Commission on July 15, 2024 Registration No. |
|
| July 15, 2024 |
At-the-Market Equity Offering Sales Agreement Exhibit 1.1 PULSE BIOSCIENCES, INC. Common Stock ($0.001 par value per share) EQUITY DISTRIBUTION AGREEMENT July 15, 2024 CANACCORD GENUITY LLC 1 Post Office Square Suite 3000 Boston, Massachusetts 02109 NEEDHAM & COMPANY, LLC 250 Park Avenue New York, New York 10177 Ladies and Gentlemen: Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions |
|
| July 15, 2024 |
Up to $60,000,000 Pulse Biosciences, Inc. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-278322 and 333-280805 PROSPECTUS SUPPLEMENT (To Prospectus dated April 8, 2024) Up to $60,000,000 Pulse Biosciences, Inc. Common Stock We have entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC and Needham & Company, LLC (jointly and severally, the “Agents”), r |
|
| July 8, 2024 |
PLSE / Pulse Biosciences, Inc. / DUGGAN ROBERT W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 15)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI |
|
| July 8, 2024 |
Exhibit 99.1 Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation Provides expanded access to FDA and prioritized review of submission MIAMI, Florida, July 8, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietar |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 8, 2024 Pulse Biosciences, Inc. |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 3, 2024 Pulse Biosciences, Inc. |
|
| July 3, 2024 |
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering Exhibit 99.1 Pulse Biosciences, Inc. Announces the Closing of its Rights Offering HAYWARD, Calif., July 3, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the final results thereof. The Company rec |
|
| June 28, 2024 |
Exhibit 99.1 Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering Oversubscribed offering expected to generate $60 million in immediate gross proceeds for the Company Warrants issued in the offering could generate up to an additional $66MM HAYWARD, Calif., June 28, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging it |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 Pulse Biosciences, Inc. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 4, 2024 |
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-278494 PROSPECTUS Pulse Biosciences, Inc. Subscription Rights to Purchase Up to 6,000,000 Units at the Initial Price Each Unit Consisting of One Share of Common Stock and Two Warrants, Each Being a Warrant to Purchase One-Half of One Share of Common Stock (and Up to 6,000,000 Shares of Common Stock Underlying the Warrants at 110% of t |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2024 Pulse Biosciences, Inc. |
|
| June 4, 2024 |
Pulse Biosciences, Inc. Announces Commencement of Rights Offering Exhibit 99.1 Pulse Biosciences, Inc. Announces Commencement of Rights Offering HAYWARD, Calif., June 4, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has commenced its previously announced rights offering of up to $60,000,000 |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc. |
|
| May 31, 2024 |
Exhibit 1.01 Conflict Minerals Report of Pulse Biosciences, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pulse Biosciences, Inc. (“Pulse Biosciences” or the “Company”) for the reporting period January 1, 2023 to December 31, 2023 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934, |
|
| May 28, 2024 |
As filed with the Securities and Exchange Commission on May 28, 2024 As filed with the Securities and Exchange Commission on May 28, 2024 Registration No. |
|
| May 20, 2024 |
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 Exhibit 99.1 Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 HAYWARD, Calif. – (BUSINESS WIRE) – May 20, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has determined a new |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2024 |
Exhibit 99.1 Pulse Biosciences Enhances Executive Leadership Team Appoints proven atrial fibrillation medical technology leader Burke T. Barrett as President and Chief Executive Officer Former President and Chief Executive Officer Kevin Danahy appointed as Chief Commercial Officer HAYWARD, Calif. [Business Wire] – May 14, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its nove |
|
| May 15, 2024 |
Exhibit 10.4 PULSE BIOSCIENCES, INC. FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This fourth amendment (this “Amendment”) is entered into effective as of May 12, 2024, by and between Kevin Danahy (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Parties entered into an employment agreement dated February 9, 2022 (as previously amended, |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2024 |
Pulse Biosciences, 2017 Inducement Equity Incentive Plan Exhibit 10.2 PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits |
|
| May 15, 2024 |
Exhibit 10.5 PULSE BIOSCIENCES, INC. FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT This fifth amendment (this “Amendment”) is entered into effective as of May 12, 2024, by and between Darrin Uecker (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Company and Executive entered into an employment agreement dated September 8, 2015 (as amend |
|
| May 15, 2024 |
Exhibit 10.3 PULSE BIOSCIENCES, INC. 2017 INDUCEMENT EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Pulse Biosciences, Inc. Amended and Restated 2017 Inducement Equity Incentive Plan (the “Plan” of the “2017 Inducement Equity Incentive Plan”)) will have the same defined meanings in this Stock Option Agreement incl |
|
| May 15, 2024 |
Exhibit 10.1 PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Burke T. Barrett (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of May 12, 2024. Certain capitalized terms used herein shall have the meanings assigned to them in Section 10 of this Agreement. 1. Duties and Scope of Employment. (a) Position an |
|
| May 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 9, 2024 |
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System Exhibit 99.1 Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System HAYWARD, Calif. [Business Wire] – May 9, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System i |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 7, 2024 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results HAYWARD, Calif. [Business Wire] – May 7, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. Recent |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 2, 2024 |
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 Exhibit 99.1 Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 HAYWARD, Calif. – (BUSINESS WIRE) – May 2, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has set the record date for th |
|
| May 1, 2024 |
PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 May 1, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-278494 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities |
|
| April 30, 2024 |
April 30, 2024 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 30, 2024 |
As filed with the Securities and Exchange Commission on April 30, 2024 As filed with the Securities and Exchange Commission on April 30, 2024 Registration No. |
|
| April 25, 2024 |
April 25, 2024 VIA EDGAR Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 25, 2024 |
As filed with the Securities and Exchange Commission on April 25, 2024 As filed with the Securities and Exchange Commission on April 25, 2024 Registration No. |
|
| April 23, 2024 |
As filed with the Securities and Exchange Commission on April 23, 2024 As filed with the Securities and Exchange Commission on April 23, 2024 Registration No. |
|
| April 23, 2024 |
April 23, 2024 VIA EDGAR Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 23, 2024 |
DEFA14A 1 plse20240418defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| April 15, 2024 |
As filed with the Securities and Exchange Commission on April 15, 2024 As filed with the Securities and Exchange Commission on April 15, 2024 Registration No. |
|
| April 15, 2024 |
April 15, 2024 Office of Industrial Applications and Services Division of Corporate Finance Securities and Exchange Commission 100 F Street, N. |
|
| April 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc. |
|
| April 4, 2024 |
PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 April 4, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-278322 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securitie |
|
| April 3, 2024 |
Form of Letter to Stockholders who are Record Holders EXHIBIT 99.2 FORM OF LETTER TO STOCKHOLDERS WHO ARE RECORD HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. [ [●], 2024] Dear Stockholder: Enclosed are materials relating to a rights offering by Pulse Biosciences, Inc., a Delaware corporation (“we,” “us,” “our,” or the “Company”), including the prospectus dated [ [ |
|
| April 3, 2024 |
Form of Beneficial Owner Election Form EXHIBIT 99.6 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024] (THE “PROSPECTUS”), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. PULSE BIOSCIENCES, INC. BENEFICIAL OWNER ELECTION FORM I (We), t |
|
| April 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc. |
|
| April 3, 2024 |
Form of Instructions As To Use of Non-Transferable Subscription Rights Certificates EXHIBIT 99.1 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024] (THE “PROSPECTUS”), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. FORM OF INSTRUCTIONS AS TO USE OF PULSE BIOSCIENCES, INC. NON-TR |
|
| April 3, 2024 |
Form of Letter to Clients of Brokers and other Nominee Holders EXHIBIT 99.4 FORM OF LETTER TO CLIENTS OF BROKERS AND OTHER NOMINEE HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. [ [●], 2024] To Our Clients: Enclosed for your consideration are the prospectus, dated [ [●], 2024] (the “Prospectus”), and the “Instructions as to Use of Pulse Biosciences, Inc. Non-Transferable Sub |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 3, 2024 |
Warrant Agency Agreement, dated April 3, 2024 EXHIBIT 4.4 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT made as of April 3, 2024, between Pulse Biosciences, Inc., a Delaware corporation (“Company”), with offices at 3957 Point Eden Way, Hayward, California 94545, and Broadridge Corporate Issuer Solutions, LLC (“Warrant Agent”), with offices at 51 Mercedes Way, Edgewood, NY 11717 (the “Warrant Agreement”). WHEREAS, the Company is engaged in |
|
| April 3, 2024 |
Form of Letter to Brokers and other Nominee Holders EXHIBIT 99.3 FORM OF LETTER TO BROKERS AND OTHER NOMINEE HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. [ [●], 2024] To Securities Dealers, Commercial Banks, Trust Companies, and Other Nominees: This letter is being distributed to securities dealers, commercial banks, trust companies, and other nominees in connec |
|
| April 3, 2024 |
Form of Subscription Rights Certificate Exhibit 4.2 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024] (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. PULSE BIOSCIENCES, INC. Incorporated under the laws of the State o |
|
| April 3, 2024 |
EXHIBIT 4.3 PULSE BIOSCIENCES, INC. Warrant To Purchase Common Stock Warrant Shares: Initial Exercise Date: , 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initia |
|
| April 3, 2024 |
Form of Nominee Holder Certification EXHIBIT 99.5 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. PULSE BIOSCIENCES, INC. UNITS SUBSCRIBED FOR UPON EXERCISE OF SUBS |
|
| March 28, 2024 |
Pulse Biosciences Announces Plans to Initiate a Rights Offering Exhibit 99.2 Pulse Biosciences Announces Plans to Initiate a Rights Offering HAYWARD, Calif. [Business Wire] – March 28, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The rights offeri |
|
| March 28, 2024 |
Exhibit 10.26 PULSE BIOSCIENCES, INC. THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This third amendment (this “Amendment”) is entered into effective as of March 26, 2024, by and between Kevin Danahy (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Parties entered into an employment agreement dated February 9, 2022 (as previously amended |
|
| March 28, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348 |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc. |
|
| March 28, 2024 |
Exhibit 4.2 PULSE BIOSCIENCES, INC. INDENTURE Dated as of , 20 [], As Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 6 1.1 Definitions 6 1.2 Other Definitions 8 1.3 Incorporation by Reference of Trust Indenture Act 8 1.4 Rules of Construction 9 ARTICLE II THE SECURITIES 9 2.1 Issuable in Series 9 2.2 Establishment of Terms of Series of Securities 9 2.3 Executio |
|
| March 28, 2024 |
Exhibit 10.27 PULSE BIOSCIENCES, INC. FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This fourth amendment (this “Amendment”) is entered into effective as of March 26, 2024, by and between Darrin Uecker (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Company and Executive entered into an employment agreement dated September 8, 2015 (as |
|
| March 28, 2024 |
Exhibit 97.1 Incentive-Based Compensation Clawback Policy Effective November 2023 Pulse Biosciences, Inc. (“Company”) has adopted this clawback policy (the “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company. To the extent this Policy applies to compensation payable to a covered person, it shall be the only clawback policy applicable to such compe |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28,2023 As filed with the Securities and Exchange Commission on March 28,2023 Registration No. |
|
| March 28, 2024 |
Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of Incorporation Ownership Position NanoBlate Corp., a Delaware Corporation Delaware 100% BioElectroMed Corp., a California Corporation California 100% Pulse Biosciences BV Netherlands 100% 2783162 Ontario Inc. Ontario 100% |
|
| March 28, 2024 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results HAYWARD, Calif. [Business Wire] – March 28, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full yea |
|
| March 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 8, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 11, 2024 |
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX Exhibit 99.1 Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System HAYWARD, Calif. [Business Wire] – March 8, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for |
|
| February 14, 2024 |
Exhibit 99.1 Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study HAYWARD, Calif. [Business Wire] – February 14, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) tec |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 9, 2024 |
Investor Deck, dated January 2024 Exhibit 99.1 |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 2, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 2, 2024 |
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX Exhibit 99.1 Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp HAYWARD, Calif. [Business Wire] – January 02, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a p |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 20, 2023 |
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Exhibit 99.1 Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif. [Business Wire] – December 20, 2023. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily |
|
| December 15, 2023 |
PLSE / Pulse Biosciences Inc / DUGGAN ROBERT W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 14)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI |
|
| December 4, 2023 |
EX-99.1 2 tm2332044d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Pulse Bio |
|
| December 4, 2023 |
PLSE / Pulse Biosciences Inc / DUGGAN ROBERT W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 13)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e) |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 21, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 21, 2023 |
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode Exhibit 99.1 Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode HAYWARD, Calif. [Business Wire] – November 21, 2023. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filin |
|
| November 13, 2023 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results Pulse Biosciences will host Third Quarter 2023 Financial Results conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023 HAYWARD, Calif. [Business Wire] – November 13, 2023. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Cell |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 10, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 29, 2023 |
PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, CA 94545 (510) 906-4600 PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, CA 94545 (510) 906-4600 August 29, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-273944 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11,2023 As filed with the Securities and Exchange Commission on August 11,2023 Registration No. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 10, 2023 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results HAYWARD, Calif. [Business Wire] – August 10, 2023 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 20, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 20, 2023 |
Investor Deck, dated July 20, 2023 Exhibit 99.1 |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc. |
|
| May 31, 2023 |
Exhibit 1.01 Conflict Minerals Report of Pulse Biosciences, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pulse Biosciences, Inc. (“Pulse Biosciences” or the “Company”) for the reporting period January 1, 2022 to December 31, 2022 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934, |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 25, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 11, 2023 |
Exhibit 99.1 Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results HAYWARD, Calif. [Business Wire] – May 11, 2023 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 11, 2023 |
PLSE / Pulse Biosciences Inc / DUGGAN ROBERT W - AMENDMENT TO FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 12)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 10, 2023 |
Pulse Biosciences, Inc. S-8 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equ |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Pulse Biosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3957 Point Eden Way Hayward, Californ |
|
| May 10, 2023 |
PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS Exhibit 99.1 PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS HAYWARD, Calif.-(BUSINESS WIRE)—May 10, 2023—Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced that it intends to deliver an irrevocable notice of redemption, on or about May |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 5, 2023 |
EX-10.2 3 ex514883.htm AMENDMENT TO EMPLOYMENT AGREEMENT, BETWEEN DARRIN UECKER AND PULSE BIOSCIENCES, INC., DATED MAY 5, 2023. Exhibit 10.2 PULSE BIOSCIENCES, INC. THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This third amendment (this “Amendment”) is entered into effective as of April 29, 2023 by and between Darrin Uecker (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Exe |
|
| May 5, 2023 |
Exhibit 10.1 PULSE BIOSCIENCES, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This second amendment (this “Amendment”) is entered into effective as of April 29, 2023 (the “Amendment Date”) by and between Kevin Danahy (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Parties entered into an employment agreement dated February 9, 2022 |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 1, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 30, 2023, between Pulse Biosciences, Inc., a Delaware corporation (the “Company”), and the purchaser identified on Exhibit A hereto (the “Purchaser”). RECITALS WHEREAS, on the terms and subject to the conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Sec |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 1, 2023 |
PULSE BIOSCIENCES ANNOUNCES $65 MILLION PRIVATE PLACEMENT Exhibit 99.1 PULSE BIOSCIENCES ANNOUNCES $65 MILLION PRIVATE PLACEMENT HAYWARD, Calif. [Business Wire] – May 1, 2023 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology and proprietary CellFX System® for the treatment of atrial fibrillation, today announced that it has entered into a stock purchase agreement |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| March 31, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348 |
|
| March 31, 2023 |
Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of Incorporation Ownership Position NanoBlate Corp., a Delaware Corporation Delaware 100% BioElectroMed Corp., a California Corporation California 100% Pulse Biosciences BV Netherlands 100% 2783162 Ontario Inc. Ontario 100% |
|
| March 30, 2023 |
EX-99.1 2 ex494874.htm PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 30, 2023 Exhibit 99.1 Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results HAYWARD, Calif. [Business Wire] – March 30, 2023 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and th |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 17, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 21, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN AGREEMENT This FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”) dated as of March 17, 2023 (the “First Amendment Effective Date”) is entered into by and among PULSE BIOSCINECES, INC., a Delaware corporation (the “Borrower”) and ROBERT DUGGAN (the “Lender”). W I T N E S E T H: WHEREAS, the Borrower and the Lender are parties to that certain Loan Agreement da |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commissio |
|
| November 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commissio |
|
| November 10, 2022 |
Pulse Biosciences Reports Third Quarter 2022 Financial Results ? HAYWARD, Calif. [Business Wire] ? November 10, 2022 ? Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX? System which harnesses and effectively controls the application of Nano-Pulse Stimulation? (NPS?) to human cells and tissue for ablation in multiple therapeutic condition |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 23, 2022 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 28, 2022 |
Pulse Biosciences, Inc. 8-K Exhibit 10.1 PULSE BIOSCIENCES, INC. AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (the ?Amendment?) is entered into effective as September 20, 2022 (the ?Amendment Date?) by and between Kevin Danahy (?Executive?) and Pulse Biosciences, Inc. (the ?Company,? and together with Executive, the ?Parties?). WHEREAS, the Parties entered into an employment agreement dated Fe |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 20, 2022 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 23, 2022 |
Pulse Biosciences, Inc. 8-K Exhibit 10.1 ******************************* LOAN AGREEMENT Dated as of September 20, 2022 by and among PULSE BIOSCIENCES, INC. as the Borrower, and ROBERT DUGGAN, as the Lender ******************************* TABLE OF CONTENTS Section Page ARTICLE I. DEFINITIONS AND ACCOUNTING TERMS 1 SECTION 1.1. Certain Defined Terms 1 SECTION 1.2. Terms Generally 5 SECTION 1.3. Comp |
|
| September 23, 2022 |
Pulse Biosciences, Inc. 8-K Exhibit 10.2 PULSE BIOSCIENCES, INC. AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (the ?Amendment?) is entered into effective as September 20, 2022 by and between Darrin Uecker (?Executive?) and Pulse Biosciences, Inc. (the ?Company,? and together with Executive, the ?Parties?). WHEREAS, the Company and Executive entered into an employment agreement dated September |
|
| September 23, 2022 |
Pulse Biosciences, Inc. 8-K Exhibit 99.1 Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation Strategic focus shifting to advance core NPS? technology in cardiac and oncology sectors activate additional executive leadership and reduce dermatologic footprint. Former Chief Commercial Officer, Kevin Danah |
|
| August 10, 2022 |
Robert W. Duggan 611 S Fort Harrison Avenue, Suite 306 Clearwater, FL 33756 ? May 27, 2022 ? ? Pulse Biosciences 3957 Point Eden Way Hayward, California 94545 Attn: Board of Directors ? Re: Indemnification of Board of Directors ? Dear Directors: ? This letter serves as formal agreement as between Robert Duggan (sometimes referred to herein as ?Indemnitor?), on one hand, and Pulse Biosciences, Inc. |
|
| August 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2022 |
Pulse Biosciences Reports Second Quarter 2022 Financial Results ? HAYWARD, Calif. [Business Wire] ? August 10, 2022 ? Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX? System powered by Nano-Pulse Stimulation? (NPS?) technology, today announced financial results for the second quarter ended June 30, 2022. ? Company Updates ? Continued active e |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Bios |
|
| July 14, 2022 |
PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 July 14, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Frank Wyman Mary Mast Re: Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 31, 2022 File No. 001-37744 Dear Ladies and Gentlemen: This letter sets forth responses on behalf o |
|
| June 13, 2022 |
PLSE / Pulse Biosciences Inc / DUGGAN ROBERT W - AMENDMENT TO FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 11)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI |
|
| June 9, 2022 |
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering Pulse Biosciences, Inc. Announces the Closing of its Rights Offering ? HAYWARD, Calif. [Business Wire] ? June 9, 2022 ? Pulse Biosciences, Inc. (Nasdaq: PLSE) (the ?Company? or ?Pulse Biosciences?), a novel bioelectric medicine company commercializing the CellFX? System powered by Nano-Pulse Stimulation? (NPS?) technology, announced today the closing of its rights offering and the final results th |
|
| June 9, 2022 |
PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 CORRESP 1 filename1.htm PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 June 9, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Frank Wyman Mary Mast Re: Pulse Biosciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 31, 2022 File No. 001-37744 Dear Ladies and Gentlemen: |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 3, 2022 |
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering ? HAYWARD, Calif. [Business Wire] ? June 3, 2022 ? Pulse Biosciences, Inc. (Nasdaq: PLSE) (the ?Company? or ?Pulse Biosciences?), a novel bioelectric medicine company commercializing the CellFX? System powered by Nano-Pulse Stimulation? (NPS?) technology, announced today preliminary results of its rights offering, which |
|
| May 31, 2022 |
SD 1 plse-20220531corresp.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 3957 Point Eden Way Hayward, Califo |
|
| May 31, 2022 |
EX-1.01 2 plse-20220531xex101.htm EXHIBIT 1.01 Exhibit 1.01 Conflict Minerals Report of Pulse Biosciences, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pulse Biosciences, Inc. (“Pulse Biosciences” or the “Company”) for the reporting period January 1, 2021 to December 31, 2021 in accordance with Rule 13p-1 (“Rule |
|
| May 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 19, 2022 |
Pulse Biosciences, Inc. Announces Changes to its Rights Offering Pulse Biosciences, Inc. Announces Changes to its Rights Offering ? HAYWARD, Calif. [Business Wire] ? May 19, 2022 ? Pulse Biosciences, Inc. (Nasdaq: PLSE) (the ?Company? or ?Pulse Biosciences?), a novel bioelectric medicine company commercializing the CellFX? System Powered by Nano-Pulse Stimulation? (NPS?) technology, announced today two changes to its current rights offering. First, the Company |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 19, 2022 |
424B3 1 ny20003901x4424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-246346 Prospectus Supplement No. 2 (to Prospectus dated August 14, 2020, as supplemented on May 4, 2022) PROSPECTUS SUPPLEMENT NO. 2 PULSE BIOSCIENCES, INC. Subscription Rights to Purchase Up to 4,032,258 of Units at the Initial Price Each Unit Consisting of 1 Share of Common Stock and a Warrant to Purchase 1 |
|
| May 13, 2022 |
As filed with the Securities and Exchange Commission on May 13, 2022 As filed with the Securities and Exchange Commission on May 13, 2022 Registration No. |
|
| May 13, 2022 |
Calculation of Filing Fee Tables ? S-8 (Form Type) ? Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities ? ? Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock 457(c) 1,188,657(2) |
|
| May 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Bio |
|
| May 11, 2022 |
Pulse Biosciences Reports First Quarter 2022 Financial Results ? HAYWARD, Calif. [Business Wire] ? May 11, 2022 ? Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX? System powered by Nano-Pulse Stimulation? (NPS?) technology, today announced financial results for the first quarter of 2022. ? Company Updates ? Increased the average CellFX System |
|
| May 4, 2022 |
PULSE BIOSCIENCES, INC. Warrant To Purchase Common Stock Exhibit 4.2 PULSE BIOSCIENCES, INC. Warrant To Purchase Common Stock Warrant Shares: Initial Exercise Date: , 2022 THIS WARRANT TO PURCHASE COMMON STOCK (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initia |
|
| May 4, 2022 |
Exhibit 99.4 FORM OF LETTER TO CLIENTS OF BROKERS AND OTHER NOMINEE HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. May 4, 2022 To Our Clients: Enclosed for your consideration are the prospectus, dated August 21, 2020, as supplemented by the prospectus supplement dated May 4, 2022 (collectively, the ?Prospectus?), |
|
| May 4, 2022 |
PULSE BIOSCIENCES, INC. BENEFICIAL OWNER ELECTION FORM Exhibit 99.6 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED AUGUST 21, 2020, AS SUPPLEMENTED BY THE PROSPECTUS SUPPLEMENT DATED MAY 4, 2022 (COLLECTIVELY, THE ?PROSPECTUS?), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLIN |
|
| May 4, 2022 |
Exhibit 99.3 FORM OF LETTER TO BROKERS AND OTHER NOMINEE HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. May 4, 2022 To Securities Dealers, Commercial Banks, Trust Companies, and Other Nominees: This letter is being distributed to securities dealers, commercial banks, trust companies, and other nominees in connect |
|
| May 4, 2022 |
Exhibit 4.3 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT made as of April 25, 2022, between Pulse Biosciences, Inc., a Delaware corporation (?Company?), with offices at 3957 Point Eden Way, Hayward, California 94545, and Broadridge Corporate Issuer Solutions, Inc. (?Warrant Agent?), with offices at 51 Mercedes Way, Edgewood, NY 11717 (the ?Warrant Agreement?). WHEREAS, the Company is engaged |
|
| May 4, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-246346 PROSPECTUS SUPPLEMENT (to prospectus dated August 21, 2020) $15,000,000 ? Pulse Biosciences, Inc. Subscription Rights to Purchase Up to 4,032,258 of Units at the Initial Price Each Unit Consisting of 1 Share of Common Stock and a Warrant to Purchase 1 Share of Common Stock (and Up to 4,032,258 of Shares of Com |
|
| May 4, 2022 |
Exhibit 99.2 FORM OF LETTER TO STOCKHOLDERS WHO ARE RECORD HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. May 4, 2022 Dear Stockholder: Enclosed are materials relating to a rights offering by Pulse Biosciences, Inc., a Delaware corporation (?we,? ?us,? ?our,? or the ?Company?), including the prospectus dated Augu |
|
| May 4, 2022 |
Exhibit 99.1 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED AUGUST 21, 2020, AS SUPPLEMENTED BY THE PROSPECTUS SUPPLEMENT DATED MAY 4, 2022 (COLLECTIVELY, THE ?PROSPECTUS?), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLIN |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2022 Pulse Biosciences, Inc. |
|
| May 4, 2022 |
Exhibit 4.1 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED AUGUST 21, 2020, AS SUPPLEMENTED BY THE PROSPECTUS SUPPLEMENT DATED MAY 4, 2022 (COLLECTIVELY, THE ?PROSPECTUS?) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLING |
|
| May 4, 2022 |
Pulse Biosciences, Inc. Announces Commencement of Rights Offering Exhibit 99.7 Pulse Biosciences, Inc. Announces Commencement of Rights Offering HAYWARD, Calif., May 4, 2022 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the ?Company? or ?Pulse Biosciences?), a novel bioelectric medicine company, today announced that it has commenced its previously announced rights offering of up to $15,000,000 of units (the ?Units,? and each, a ?Unit?) at the Initial Price (as defin |
|
| May 4, 2022 |
Exhibit 99.5 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED AUGUST 21, 2020, AS SUPPLEMENTED BY THE PROSPECTUS SUPPLEMENT DATED MAY 4, 2022 (COLLECTIVELY, THE ?PROSPECTUS?) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLING |
|
| April 14, 2022 |
Pulse Biosciences, Inc. Announces Rights Offering Pulse Biosciences, Inc. Announces Rights Offering HAYWARD, Calif. [Business Wire] - April 14, 2022 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the ?Company? or ?Pulse Biosciences?), a novel bioelectric medicine company, today announced that the Company?s Board of Directors has approved a rights offering available to all holders of record of the Company?s common stock, par value $0.001 per share (the |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission F |
|
| April 1, 2022 |
DEF 14A 1 plse-20220519xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by |
|
| April 1, 2022 |
DEFA14A 1 plse-20220401xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted b |
|
| March 31, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission F |
|
| March 31, 2022 |
Employment Agreement between Mitchell E. Levinson and the Registrant PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Mitch Levinson (?Executive?) and Pulse Biosciences, Inc. (the ?Company?), as of August 17, 2021. 1. Duties and Scope of Employment. (a) Position and Duties. As of August 19, 2021 (the ?Start Date?), Executive will serve as the Company?s Chief Strategy Officer operating f |
|
| March 31, 2022 |
Employment Agreement between Kevin Danahy and the Registrant ? PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Kevin Danahy (?Executive?) and Pulse Biosciences, Inc. (the ?Company?), as of February 9, 2022. 1. Duties and Scope of Employment. (a) Position and Duties. As of February 14, 2022 (the ?Start Date?), Executive will serve as the Company?s Chief Commercial Officer operat |
|
| March 31, 2022 |
Exhibit 21.1 List of Subsidiaries ? ? Subsidiary Jurisdiction of Incorporation Ownership Position NanoBlate Corp., a Delaware Corporation Delaware 100% BioElectroMed Corp., a California Corporation California 100% Pulse Biosciences BV Netherlands 100% 2783162 Ontario Inc. Ontario 100% ? |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Bioscienc |
|
| March 31, 2022 |
Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results ? HAYWARD, Calif. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 18, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission F |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission |
|
| February 15, 2022 |
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer EX-99.1 2 plse-20220209xex991.htm EX-99.1 Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer HAYWARD, Calif. [Business Wire] – February 9, 2022. Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Kevin Danahy to t |
|
| February 8, 2022 |
Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission HAYWARD, Calif. |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission |
|
| January 11, 2022 |
Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results HAYWARD, Calif. |
|
| January 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 11, 2022 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2021 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commissio |
|
| November 15, 2021 |
PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except par value) Pulse Biosciences Reports Third Quarter 2021 Financial Results ? HAYWARD, Calif. [Business Wire] ? November 15, 2021 ? Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX? System powered by Nano-Pulse Stimulation? (NPS?) technology, today announced financial results for the third quarter of 2021. ? Recent Highlights ? Achieved third quarter 2021 |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse |
|
| November 15, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2021 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commissio |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 4, 2021 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37744 46-5696597 (State or other jurisdiction of incorporation) (Commission |
|
| October 6, 2021 |
? ? Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors ? HAYWARD, Calif. |
